Chimeric antigen receptor T-cell therapy conferred sustained benefit to individuals with high-risk smoldering multiple myeloma, according to phase 2 trial results. All patients who received a single ...

Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use ...

Four of nine patients responded to the mesothelin-directed therapy, which uses a multi-chain receptor borrowed from NK cells, ...

Early-line data appears encouraging, with MajesTEC-3 complemented by emerging newly diagnosed data showing near-universal ...

KACTUS, a leading recombinant protein manufacturer, has published a technical framework for engineering 2+1 and trispecific T-cell engager (TCE) therapeutics.

Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3’s advancement ...

Researchers have engineered a synthetic Notch receptor system to directly label and profile cells interacting with developing T cells in the thymus. The study identified a broad network of immune and ...

Impaired wound healing and pathological scarring remain major clinical challenges, closely linked to dysregulation of the ...

Overall, TherVacB was found to be safe, well-tolerated, and highly immunogenic among the healthy study participants.

Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s ...

Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...

Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...